(19)
(11) EP 4 816 058 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24824660.5

(22) Date of filing: 26.11.2024
(51) International Patent Classification (IPC): 
A61P 25/00(2006.01)
C07K 16/28(2006.01)
A61P 29/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2887; C07K 2317/24; A61P 25/00; G16H 50/70; A61P 29/00; G16H 20/17; G16H 50/20
(86) International application number:
PCT/US2024/057416
(87) International publication number:
WO 2025/117516 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 30.11.2023 US 202363604675 P

(71) Applicant: GENZYME CORPORATION
Cambridge, Massachusetts 02141 (US)

(72) Inventor:
  • MOLONY, Cliona Marie
    Cambridge, Massachusetts 02141 (US)

(74) Representative: Ipsilon 
12 Avenue d'Italie
75013 Paris
75013 Paris (FR)

   


(54) METHODS FOR TREATING CD20-RELATED DISORDERS